Oral News and Research

RSS

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, and ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the companies have entered into a strategic collaboration for the further clinical development and commercialization of CMX157.

18 Dec 2014

NPS MedicineWise urges travellers to be medicinewise this holiday season

As many Australians prepare to travel both interstate and overseas this holiday season, NPS MedicineWise is urging people to be medicinewise when travelling with their medicines.

16 Dec 2014

Scientists validate oral vaccine delivery system to combat global health threats

Scientists at The Forsyth Institute and Tufts University have succeeded in describing and validating a unique system of oral vaccine delivery using a common bacteria found in the mouth.

16 Dec 2014

Postoperative recurrent disease affects NSCLC survival after gefitinib

Patients with postoperative recurrent non-small-cell lung cancer harbouring epidermal growth factor receptor mutations have longer progression-free and overall survival with gefitinib treatment, than those with stage IV disease, Japanese researchers report.

15 Dec 2014

New holistic approach to cancer treatment

The University of Texas MD Anderson Cancer Center and UnitedHealthcare have launched a pilot to explore a new cancer care payment model for head and neck cancers that focuses on quality patient care and outcomes. The collaboration is among the first using bundled payments in a large, comprehensive cancer center.

15 Dec 2014

Many college students regard hookah smoking safer than smoking cigarettes

Despite emerging evidence otherwise, many college students consider hookah smoking safer than smoking cigarettes, reports a University of South Florida College of Public Health study published this month by the Centers for Disease Control and Prevention.

14 Dec 2014

Postoperative recurrent disease affects NSCLC survival after gefitinib

12 Dec 2014

$Children who sustain open bone fractures can heal safely without surgery$

Children who sustain open bone fractures can heal safely without surgery

Many children who sustain so-called open bone fractures in the forearm or lower leg can, and do, heal safely without surgery, according to the results of a small study led by investigators at the Johns Hopkins Children's Center.

11 Dec 2014

Revolutionary new approach uses advanced technology to remove head and neck cancer tumors

In a groundbreaking new study, UCLA researchers have for the first time advanced a surgical technique performed with the help of a robot to successfully access a previously-unreachable area of the head and neck.

10 Dec 2014

Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Bayer HealthCare and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness (or onchocerciasis). The world's second leading infectious cause of blindness, river blindness is a neglected tropical disease caused by a filarial worm.

10 Dec 2014

Laughing gas could be used as treatment for severe depression

Nitrous oxide, or laughing gas, has shown early promise as a potential treatment for severe depression in patients whose symptoms don't respond to standard therapies. The pilot study, at Washington University School of Medicine in St. Louis, is believed to be the first research in which patients with depression were given laughing gas.

10 Dec 2014

Study: Simeprevir-based therapy proves effective in treating chronic HCV infection

Researchers at Penn Medicine, in collaboration with a multi-center international team, have shown that a protease inhibitor, simeprevir, a once a day pill, along with interferon and ribavirin has proven as effective in treating chronic Hepatitis C virus infection (HCV) as telaprevir with interferon and ribavirin, the standard of care in developing countries.

10 Dec 2014

MOVENTIG (naloxegol) receives EC approval for treatment of opioid-induced constipation

Nektar Therapeutics reported partner AstraZeneca today announced that MOVENTIG (naloxegol) has been granted Marketing Authorisation by the European Commission for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).

9 Dec 2014

ContraVir begins pharmacokinetic study of FV-100 for treating shingles

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has initiated a pharmacokinetic (PK) study of FV-100, the Company's clinical-stage antiviral for treating shingles.

9 Dec 2014

Novartis' JUMP study reinforces safety, efficacy of Jakavi (ruxolitinib) for myelofibrosis treatment

Novartis today announced data from the largest clinical trial of myelofibrosis patients treated with Jakavi (ruxolitinib), supporting the safety profile and efficacy benefit as measured in primary and secondary endpoints respectively.

9 Dec 2014

CTI BioPharma presents data from Phase 3 trial of pacritinib in AML patients at ASH 2014

CTI BioPharma Corp. today announced data showing treatment with pacritinib, an investigational oral multikinase inhibitor in Phase 3 clinical development, preferentially killed acute myeloid leukemia (AML) cells with FLT3 mutations, overcame stromal protection and suppressed leukemic outgrowth from stroma adherent AML cells in both medium-term (7-14 days) and long-term (5-6 weeks) assays.

9 Dec 2014

$IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL$

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL).

9 Dec 2014

Study points to need for improving pediatric benefits under the Affordable Care Act

An article published in the Health Affairs December issue is the first ever comprehensive analysis to investigate the Affordable Care Act's (ACA) Essential Health Benefit (EHB) as it relates to children. The study found that the EHB has resulted in a state-by-state patchwork of coverage for children and adolescents that has significant exclusions, particularly for children with developmental disabilities and other special health care needs.

9 Dec 2014

Studies presented at ASH meeting compare new, standard-of-care treatments for blood clots

Studies presented at the 56th American Society of Hematology Annual Meeting and Exposition compare new and standard-of-care treatments for blood clots and further illuminate clot risks in vulnerable populations, such as cancer patients.

8 Dec 2014

Henry Ford Hospital recruits patients to participate in brain cancer clinical trial

Henry Ford Hospital today announced that it is actively recruiting patients to participate in a clinical trial taking place at the Hermelin Brain Tumor Center which is showing promising results in patients with brain cancer.

8 Dec 2014

Oral News and Research

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

NPS MedicineWise urges travellers to be medicinewise this holiday season

Scientists validate oral vaccine delivery system to combat global health threats

Postoperative recurrent disease affects NSCLC survival after gefitinib

New holistic approach to cancer treatment

Many college students regard hookah smoking safer than smoking cigarettes

Postoperative recurrent disease affects NSCLC survival after gefitinib

Children who sustain open bone fractures can heal safely without surgery

Revolutionary new approach uses advanced technology to remove head and neck cancer tumors

Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Laughing gas could be used as treatment for severe depression

Study: Simeprevir-based therapy proves effective in treating chronic HCV infection

MOVENTIG (naloxegol) receives EC approval for treatment of opioid-induced constipation

ContraVir begins pharmacokinetic study of FV-100 for treating shingles

Novartis' JUMP study reinforces safety, efficacy of Jakavi (ruxolitinib) for myelofibrosis treatment

CTI BioPharma presents data from Phase 3 trial of pacritinib in AML patients at ASH 2014

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

Study points to need for improving pediatric benefits under the Affordable Care Act

Studies presented at ASH meeting compare new, standard-of-care treatments for blood clots

Henry Ford Hospital recruits patients to participate in brain cancer clinical trial

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News